Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Juan Francisco Rodríguez-Moreno"'
Autor:
María Dolores Fenor, Sergio Ruiz-Llorente, Juan Francisco Rodríguez-Moreno, Eduardo Caleiras, Juan Carlos Torrego, Elena Sevillano-Fernández, Paloma Navarro, Mónica Yagüe-Fernández, Sandra Amarilla-Quintana, Arantzazu Barquín, Jesús García-Donas
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 24(12)
The identification of subpopulations harboring druggable targets has become a major step forward in the subclassification of solid tumors into small groups suitable for specific therapies. BRAF fusions represent a paradigm of uncommon and targetable
Autor:
Juan Francisco, Rodríguez-Moreno, María, Apellaniz-Ruiz, Juan María, Roldan-Romero, Ignacio, Durán, Luis, Beltrán, Cristina, Montero-Conde, Alberto, Cascón, Mercedes, Robledo, Jesus, García-Donas, Cristina, Rodríguez-Antona
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 15(11)
mTOR pathway inhibitors are important drugs for the treatment of advanced renal cell carcinoma (RCC). However, no valid predictive markers have been identified to guide treatment selection and identify patients who are sensitive to these drugs. Mutat
Autor:
Sergio Ruiz, María Dolores Fenor de la Maza, Juan Francisco Rodríguez Moreno, Elena Sevillano, Paloma Navarro, Sandra Amarilla, Teresa García Donas, Eduardo Caleiras, Juan Carlos Torrego, Jesus García Donas
Publikováno v:
Cancer Research. 79:4475-4475
Identification of “agnostic” genetic drivers in cancer is foreseen as a major step forward in precision medicine. Thus, treatment selection could be based on the molecular background of the disease rather than on tumor histology in the near futur
Autor:
Jesus Garcia-Donas, Diego Martínez-Urbistondo, Kyra Velázquez Kennedy, Paula Villares, Arántzazu Barquin, Andrea Dominguez, Juan Francisco Rodriguez-Moreno, Elena Caro, Rafael Suarez del Villar, Estanislao Nistal-Villan, Monica Yagüe, Maria Ortiz, Maria Barba, Sergio Ruiz-Llorente, Miguel Quiralte, Massimiliano Zanin, Cristina Rodríguez, Paloma Navarro, Pedro Berraondo, Rodrigo Madurga
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundManaging the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.MethodsWe designed a randomized phase II clinical trial to determine whether the comb
Externí odkaz:
https://doaj.org/article/3ee849271a0c45228839d81a26042e68
Autor:
José A. García-Sáenz, Eduardo Díaz-Rubio, Juan Francisco Rodríguez Moreno, Teresa Alonso Gordoa, Francisco José Hernández Pérez
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 13(7)
Targeted therapies alone or combined with chemotherapy have improved response rates as well as the progression-free survival and overall survival in several solid tumors. Trastuzumab is a monoclonal antibody with a revolutionary effect on tumoral bre